FDA Class II Recall: RC Outsourcing's Bevacizumab Syringes Pulled Over Sterility Concerns
RC Outsourcing, LLC initiated a Class II recall for 2,669 Bevacizumab syringes from its Lowellville, OH facility due to sterility assurance concerns. This voluntary action, terminated January 5, 2026, impacts nationwide US distribution. Procurement and regulatory teams must scrutinize compounded sterile product suppliers, reinforcing robust quality oversight to mitigate patient safety risks and supply chain disruptions.
FDA Class II Recall: Sterility Concerns for RC Outsourcing's Bevacizumab Syringes
RC Outsourcing, LLC, based in Lowellville, OH, initiated a voluntary, firm-initiated Class II recall (D-0003-2026) for 2,669 syringes of Bevacizumab 1.75 mg/0.07 mL, intended for intravitreal use. This critical action, commenced on September 22, 2025, stemmed from a lack of assurance of sterility, posing a significant risk to patient safety, particularly given the product's direct administration into the eye. The affected lots include 20250708-768A26 (BUD: Oct 06, 2025), 20250715-944DF2 (BUD: Oct 13, 2025), 20250722-55C603 (BUD: Oct 20, 2025), and 20250722-5DC113 (BUD: Oct 20, 2025). The recall was distributed nationwide in the US and officially terminated by the FDA on January 5, 2026. For procurement directors, this event underscores the paramount importance of stringent supplier qualification for compounded sterile products. The potential for microbial contamination in intravitreal injections can lead to severe adverse events, including vision loss or endophthalmitis, directly impacting patient outcomes and incurring substantial liability for healthcare providers and purchasing organizations. Regulatory affairs heads must ensure their organizations have robust protocols for assessing and responding to such recalls, verifying that all affected product is identified and removed from circulation promptly.
Facility Profile: RC Outsourcing's Role in Compounded Sterile Products
RC Outsourcing, LLC operates from its facility at 102 E Water St, Lowellville, OH 44436-1117, serving as a critical provider of compounded sterile preparations, including specialized ophthalmic injectables like Bevacizumab. While specific capacity or market share data for this facility is not publicly detailed, its role in distributing 2,669 syringes nationwide highlights its significance within the US healthcare supply chain for customized pharmaceutical solutions. For business development executives, this recall signals the inherent risks and heightened regulatory scrutiny associated with the sterile compounding sector. The facility's location in Ohio, a state with a significant pharmaceutical manufacturing presence, places it within a region under constant FDA oversight. Supply chain VPs must recognize that outsourcing facilities, while offering vital access to tailored medications, demand rigorous due diligence beyond standard API or finished product manufacturers. The 'Rx Only, Hospital/Office Use Only' designation for the Bevacizumab product indicates its direct supply to clinical settings, making the integrity of the Lowellville operation directly consequential for patient care and the operational continuity of medical practices across the country. This event necessitates a re-evaluation of risk profiles for all partners involved in the sterile compounding ecosystem.
Supply Chain Exposure: Mitigating Risks for Intravitreal Bevacizumab
The nationwide distribution of RC Outsourcing's recalled Bevacizumab syringes exposes a broad segment of the US healthcare system, particularly ophthalmology clinics and hospitals, to supply chain disruptions and patient safety risks. As a compounded sterile product, Bevacizumab for intravitreal injection is often sourced by healthcare providers seeking cost-effective alternatives or specific dosages not commercially available from original manufacturers. Procurement directors must immediately assess their inventory of this specific product and verify its lot numbers against the recalled batches (20250708-768A26, 20250715-944DF2, 20250722-55C603, 20250722-5DC113). The 'lack of assurance of sterility' for an intravitreal product is a critical failure, as direct injection into the eye bypasses the body's natural defenses, increasing the risk of severe infections. This incident highlights the vulnerability of relying on single-source compounded sterile product suppliers without robust secondary qualification. Supply chain VPs should implement a multi-source strategy for critical compounded medications, ensuring that alternative, fully qualified suppliers are identified and vetted. This proactive approach minimizes the impact of recalls, safeguards patient health, and protects the reputation and financial stability of healthcare organizations. Business development executives should also consider the market implications, as this recall may shift demand towards more established pharmaceutical manufacturers or compounding pharmacies with demonstrably superior quality systems.
Alternative Supplier Strategies for Compounded Sterile Injectables
In the wake of RC Outsourcing's Bevacizumab recall, procurement teams must proactively identify and qualify alternative suppliers for compounded sterile injectables, especially those critical for ophthalmic care. Given the absence of specific alternative suppliers in the knowledge graph for RC Outsourcing, the focus shifts to general best practices for sourcing in this specialized market. Procurement directors should prioritize compounding pharmacies or 503B outsourcing facilities with impeccable FDA compliance records, evidenced by recent inspection outcomes and a history free of sterility-related recalls. Key qualification criteria must include robust aseptic processing controls, comprehensive environmental monitoring programs, and stringent personnel training. Geographic diversity among suppliers can also mitigate regional supply chain shocks. Qualification timelines for new sterile compounding partners can range from six to twelve months, encompassing facility audits, quality system reviews, and stability data evaluation. Supply chain VPs should initiate these processes immediately to build resilience. Furthermore, regulatory affairs heads must ensure that any new supplier's regulatory filings and product specifications align with their organization's internal quality standards and patient safety protocols. This strategic diversification is not merely about avoiding future disruptions but about upholding the highest standards of patient care and regulatory compliance in a complex pharmaceutical landscape.
Broader Regulatory Landscape: Sterility Risks in Compounding
The RC Outsourcing recall for lack of sterility assurance is not an isolated incident but reflects a persistent challenge within the broader sterile compounding industry. The ChemLifeIntel Knowledge Graph highlights a parallel event: Essential Wellness Pharma's Progesterone Injection recall in June 2026, also due to sterility assurance failures. This recurring theme underscores the critical need for enhanced vigilance from regulatory affairs heads and quality assurance teams. The FDA maintains strict guidelines for compounding pharmacies and outsourcing facilities (503B facilities) under the Drug Quality and Security Act (DQSA), specifically regarding aseptic processing and environmental controls. Failures in these areas directly translate to Class II or even Class I recalls, carrying severe implications for patient safety and significant operational and reputational damage for the firms involved. For procurement directors, this trend mandates a more rigorous audit schedule and a deeper dive into the quality culture of their compounding partners. It is insufficient to merely review documentation; on-site audits focusing on actual aseptic techniques, gowning procedures, and facility maintenance are crucial. Business development executives should recognize that companies demonstrating superior quality and compliance in sterile compounding will gain a competitive advantage, as healthcare providers increasingly prioritize reliability and safety over marginal cost savings in this high-risk segment.
Recall Termination and Future Compliance Expectations
The FDA officially terminated the Class II recall for RC Outsourcing's Bevacizumab syringes on January 5, 2026, indicating that the firm has completed the necessary actions to remove the affected product from the market. However, termination of a recall does not absolve the firm of ongoing regulatory scrutiny or the need for sustained compliance. For regulatory affairs heads, this signifies that while the immediate crisis is resolved, the underlying issues that led to the 'lack of assurance of sterility' must be thoroughly investigated and remediated to prevent recurrence. The FDA will expect RC Outsourcing to implement robust corrective and preventive actions (CAPAs) addressing the root cause of the sterility failure. This typically involves re-evaluating aseptic processing environments, personnel training, quality control testing, and environmental monitoring programs. Procurement directors and supply chain VPs should seek assurances from RC Outsourcing regarding these CAPAs, requesting detailed documentation and potentially conducting follow-up audits to confirm their effectiveness. Failure to demonstrate sustained compliance could lead to further FDA enforcement actions, including Warning Letters, injunctions, or even facility closure. This event serves as a critical reminder that continuous vigilance over supplier quality systems is essential for safeguarding both patient health and the integrity of the pharmaceutical supply chain.